Literature DB >> 32522893

Changes in kidney function markers after bariatric surgery in morbidly obese patients.

Soon Hyo Kwon1.   

Abstract

Entities:  

Year:  2020        PMID: 32522893      PMCID: PMC7321673          DOI: 10.23876/j.krcp.20.058

Source DB:  PubMed          Journal:  Kidney Res Clin Pract        ISSN: 2211-9132


× No keyword cloud information.
Obesity is a global health problem that is strongly associated with developing type 2 diabetes mellitus (DM), cardiovascular disease, cerebrovascular accidents, and some malignancies. Additionally, obesity is a major risk factor for the development and progression of chronic kidney disease (CKD) [1]. Bariatric surgery is a proven and effective method for sustaining weight loss, lowering blood pressure, improving glycemic control, and inducing the remission of DM [2]. Additionally, renal parameters may be improved in obese patients after bariatric surgery. A meta-analysis showed that bariatric surgery reduced the unindexed measured glomerular filtration rate (mGFR) in patients with a normal or high GFR, which is suggestive of a return to normofiltration from the hyperfiltration of single nephron GFR [3]. Our previous study also found the GFR in obese patients decreased to an age- and sex-matched normal GFR range after surgery [4]. The presence of albuminuria or proteinuria also decreased after surgery-induced weight reduction [5]. Is bariatric surgery safe or beneficial in patients with CKD or end-stage renal disease? Recently, bariatric surgery has been reported to be relatively safe in patients with CKD, although postoperative complications were slightly more frequent in these patients than in the general obese population [6]. In short, bariatric surgery is beneficial for obese patients with CKD who have preserved kidney function. Although several studies have reported that obesity is paradoxically associated with better outcomes in advanced CKD, the presence of morbid obesity in CKD patients is related to the progression of kidney dysfunction [7]. Thus, nephrologists should consider bariatric surgery for morbidly obese patients with CKD. In this issue of Kidney Research and Clinical Practice (KRCP), Khalil et al [8] showed improvement in kidney function biomarkers after bariatric surgery. Their single-center prospective study enrolled 44 obese patients, and the eGFR, albuminuria, and kidney injury molecule (KIM-1) were assessed both before and six months after bariatric surgery. They found that bariatric surgery decreased the serum KIM-1 level and produced albuminuria as well as a lower BMI. The serum KIM-1 level was weakly but significantly correlated with albuminuria and the serum creatinine level before and after surgery. KIM-1 is a type 1 transmembrane glycoprotein with two extracellular domains. Following injury, the extracellular domains of KIM-1 separate from the cell surface and enter the systemic circulation and then the urine [9]. Treatment of kidney disease could decrease urinary KIM-1 levels [10]. Thus, the urinary KIM-1 level is a biomarker for early detection of kidney injury and for assessing a patient’s therapeutic response to kidney disease. Accumulating evidence indicates that circulating (blood) KIM-1 as well as the urinary KIM-1 levels can be a diagnostic and prognostic biomarker in various kidney diseases, such as acute kidney injury, renal cell carcinoma, urinary tract infection, and diabetic nephropathy (Table 1) [9,11,12]. We found that the urinary KIM-1 was elevated in obesity but decreased following bariatric surgery [10]. Glomerular hyperfiltration, high blood pressure, and concomitant DM in obese patients may trigger tubular cell injury. Consistent with this information, the authors found that circulating KIM-1 levels decreased after weight reduction in association with improved glycosylated hemoglobin levels.
Table 1

A literature review of the circulating kidney injury molecule-1 (KIM-1) in kidney disease

Author (year)Serum/plasmaNumber of patientsSummary of results
Sabbisetti et al [9](2014)Plasma18Increased KIM-1 levels in acute kidney injury patients.
46Increased KIM-1 levels in chronic kidney disease of various etiologies.
Serum124KIM-1 levels predicted the rate of eGFR loss and risk of end-stage renal disease in type 1 diabetes.
Scelo et al [11](2018)Plasma380KIM-1 levels predicted the RCC incidence for up to five years.
Krzemień et al [12](2019)Serum101Increased KIM-1 levels are associated with the presence of febrile urinary tract infection in infants.

eGFR, estimated glomerular filtration rate; RCC, renal cell carcinoma.

Interestingly, the reduction in the circulating KIM-1 level was greater in obese patients without albuminuria than it was in those with microalbuminuria [8]. The authors assumed that albuminuria would represent a more severe degree of kidney injury, and weight reduction after bariatric surgery would not improve kidney function in the albuminuria group. However, the link between microalbuminuria and tubular injury remains unclear. In addition, the levels of circulating KIM-1 before surgery did not differ according to the presence of albuminuria. The change in albuminuria in CKD patients after treatment may be a surrogate endpoint for the progression of kidney diseases [13]. Whether the reduction of blood or urine KIM-1 levels due to treatment may lead to favorable renal outcomes is yet to be investigated. Thus, it is unclear whether the considerable reduction of KIM-1 after bariatric surgery would be beneficial in obese patients. The use of sleeve gastrectomy in bariatric surgery is a crucial strength of this study. This strategy offers important metabolic advantages over other surgical techniques for weight reduction, such as laparoscopic adjustable gastric banding, roux-en-Y gastric bypass, and biliopancreatic diversion with duodenal switch. Different surgeries could variably alter kidney function parameters; this effect is likely due to anatomic and functional differences induced by the specific surgical procedures. In addition, the participants in this study demonstrated preserved eGFRs and no overt albuminuria. A homogenous patient population with mild renal injury might have produced more favorable results in this study. However, this investigation did not measure the urinary KIM-1 level in obese patients. The assessment of urinary and circulating KIM-1 levels both before and after surgery may have revealed more precise KIM-1 behavior according to the patients’ BMI status. Additional large prospective studies are warranted to determine if different surgical procedures may influence the levels of urinary and circulating KIM-1 and whether the degree of KIM-1 reduction would be associated with an improvement in kidney function in obese patients. In summary, the level of KIM-1 was reduced by sleeve gastrectomy, and bariatric surgery may be associated with improvement of renal tubular injury in obese patients. Taken together, the role of tubular injury in the mechanisms of obesity-related renal outcomes needs to be determined. Further studies are required to determine whether urinary and circulating KIM-1 levels are earlier biomarkers than microalbuminuria in obesity-induced renal injury.
  13 in total

1.  Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials.

Authors:  Hiddo J L Heerspink; Tom Greene; Hocine Tighiouart; Ron T Gansevoort; Josef Coresh; Andrew L Simon; Tak Mao Chan; Fan Fan Hou; Julia B Lewis; Francesco Locatelli; Manuel Praga; Francesco Paolo Schena; Andrew S Levey; Lesley A Inker
Journal:  Lancet Diabetes Endocrinol       Date:  2019-01-08       Impact factor: 32.069

2.  Predictors of postoperative eGFR change and resolution of hyperfiltration in obese patients following bariatric surgery.

Authors:  Sinae Lee; Suyeon Park; Mi Kyung Kwak; Hye Ran Kang; Yongjin Kim; Soon Hyo Kwon
Journal:  Surg Obes Relat Dis       Date:  2017-05-04       Impact factor: 4.734

3.  KIM-1 as a Blood-Based Marker for Early Detection of Kidney Cancer: A Prospective Nested Case-Control Study.

Authors:  Ghislaine Scelo; David C Muller; Elio Riboli; Mattias Johansson; Amanda J Cross; Paolo Vineis; Konstantinos K Tsilidis; Paul Brennan; Heiner Boeing; Petra H M Peeters; Roel C H Vermeulen; Kim Overvad; H Bas Bueno-de-Mesquita; Gianluca Severi; Vittorio Perduca; Marina Kvaskoff; Antonia Trichopoulou; Carlo La Vecchia; Anna Karakatsani; Domenico Palli; Sabina Sieri; Salvatore Panico; Elisabete Weiderpass; Torkjel M Sandanger; Therese H Nøst; Antonio Agudo; J Ramón Quirós; Miguel Rodríguez-Barranco; Maria-Dolores Chirlaque; Timothy J Key; Prateek Khanna; Joseph V Bonventre; Venkata S Sabbisetti; Rupal S Bhatt
Journal:  Clin Cancer Res       Date:  2018-07-23       Impact factor: 12.531

4.  Weight loss and proteinuria: systematic review of clinical trials and comparative cohorts.

Authors:  Farsad Afshinnia; Timothy J Wilt; Sue Duval; Abbas Esmaeili; Hassan N Ibrahim
Journal:  Nephrol Dial Transplant       Date:  2009-11-27       Impact factor: 5.992

Review 5.  The dual roles of obesity in chronic kidney disease: a review of the current literature.

Authors:  Connie M Rhee; Seyed-Foad Ahmadi; Kamyar Kalantar-Zadeh
Journal:  Curr Opin Nephrol Hypertens       Date:  2016-05       Impact factor: 2.894

6.  National Postoperative Bariatric Surgery Outcomes in Patients with Chronic Kidney Disease and End-Stage Kidney Disease.

Authors:  Jordana B Cohen; Colleen M Tewksbury; Samuel Torres Landa; Noel N Williams; Kristoffel R Dumon
Journal:  Obes Surg       Date:  2019-03       Impact factor: 4.129

Review 7.  Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis.

Authors:  Sankar D Navaneethan; Hans Yehnert; Fady Moustarah; Martin J Schreiber; Philip R Schauer; Srinivasan Beddhu
Journal:  Clin J Am Soc Nephrol       Date:  2009-09-17       Impact factor: 8.237

8.  Blood kidney injury molecule-1 is a biomarker of acute and chronic kidney injury and predicts progression to ESRD in type I diabetes.

Authors:  Venkata S Sabbisetti; Sushrut S Waikar; Daniel J Antoine; Adam Smiles; Chang Wang; Abinaya Ravisankar; Kazumi Ito; Sahil Sharma; Swetha Ramadesikan; Michelle Lee; Rebeccah Briskin; Philip L De Jager; Thanh Thu Ngo; Mark Radlinski; James W Dear; Kevin B Park; Rebecca Betensky; Andrzej S Krolewski; Joseph V Bonventre
Journal:  J Am Soc Nephrol       Date:  2014-06-05       Impact factor: 10.121

9.  Health Effects of Overweight and Obesity in 195 Countries over 25 Years.

Authors:  Ashkan Afshin; Mohammad H Forouzanfar; Marissa B Reitsma; Patrick Sur; Kara Estep; Alex Lee; Laurie Marczak; Ali H Mokdad; Maziar Moradi-Lakeh; Mohsen Naghavi; Joseph S Salama; Theo Vos; Kalkidan H Abate; Cristiana Abbafati; Muktar B Ahmed; Ziyad Al-Aly; Ala’a Alkerwi; Rajaa Al-Raddadi; Azmeraw T Amare; Alemayehu Amberbir; Adeladza K Amegah; Erfan Amini; Stephen M Amrock; Ranjit M Anjana; Johan Ärnlöv; Hamid Asayesh; Amitava Banerjee; Aleksandra Barac; Estifanos Baye; Derrick A Bennett; Addisu S Beyene; Sibhatu Biadgilign; Stan Biryukov; Espen Bjertness; Dube J Boneya; Ismael Campos-Nonato; Juan J Carrero; Pedro Cecilio; Kelly Cercy; Liliana G Ciobanu; Leslie Cornaby; Solomon A Damtew; Lalit Dandona; Rakhi Dandona; Samath D Dharmaratne; Bruce B Duncan; Babak Eshrati; Alireza Esteghamati; Valery L Feigin; João C Fernandes; Thomas Fürst; Tsegaye T Gebrehiwot; Audra Gold; Philimon N Gona; Atsushi Goto; Tesfa D Habtewold; Kokeb T Hadush; Nima Hafezi-Nejad; Simon I Hay; Masako Horino; Farhad Islami; Ritul Kamal; Amir Kasaeian; Srinivasa V Katikireddi; Andre P Kengne; Chandrasekharan N Kesavachandran; Yousef S Khader; Young-Ho Khang; Jagdish Khubchandani; Daniel Kim; Yun J Kim; Yohannes Kinfu; Soewarta Kosen; Tiffany Ku; Barthelemy Kuate Defo; G Anil Kumar; Heidi J Larson; Mall Leinsalu; Xiaofeng Liang; Stephen S Lim; Patrick Liu; Alan D Lopez; Rafael Lozano; Azeem Majeed; Reza Malekzadeh; Deborah C Malta; Mohsen Mazidi; Colm McAlinden; Stephen T McGarvey; Desalegn T Mengistu; George A Mensah; Gert B M Mensink; Haftay B Mezgebe; Erkin M Mirrakhimov; Ulrich O Mueller; Jean J Noubiap; Carla M Obermeyer; Felix A Ogbo; Mayowa O Owolabi; George C Patton; Farshad Pourmalek; Mostafa Qorbani; Anwar Rafay; Rajesh K Rai; Chhabi L Ranabhat; Nikolas Reinig; Saeid Safiri; Joshua A Salomon; Juan R Sanabria; Itamar S Santos; Benn Sartorius; Monika Sawhney; Josef Schmidhuber; Aletta E Schutte; Maria I Schmidt; Sadaf G Sepanlou; Moretza Shamsizadeh; Sara Sheikhbahaei; Min-Jeong Shin; Rahman Shiri; Ivy Shiue; Hirbo S Roba; Diego A S Silva; Jonathan I Silverberg; Jasvinder A Singh; Saverio Stranges; Soumya Swaminathan; Rafael Tabarés-Seisdedos; Fentaw Tadese; Bemnet A Tedla; Balewgizie S Tegegne; Abdullah S Terkawi; J S Thakur; Marcello Tonelli; Roman Topor-Madry; Stefanos Tyrovolas; Kingsley N Ukwaja; Olalekan A Uthman; Masoud Vaezghasemi; Tommi Vasankari; Vasiliy V Vlassov; Stein E Vollset; Elisabete Weiderpass; Andrea Werdecker; Joshua Wesana; Ronny Westerman; Yuichiro Yano; Naohiro Yonemoto; Gerald Yonga; Zoubida Zaidi; Zerihun M Zenebe; Ben Zipkin; Christopher J L Murray
Journal:  N Engl J Med       Date:  2017-06-12       Impact factor: 91.245

10.  Kidney injury molecule-1: A potential marker of renal recovery after laparoscopic sleeve gastrectomy.

Authors:  Rania Khalil; Hosam Elghadban; Moustafa Abdelsalam; Mona Tawfik
Journal:  Kidney Res Clin Pract       Date:  2020-06-30
View more
  3 in total

1.  Effect of diabetes on exosomal miRNA profile in patients with obesity.

Authors:  Hyoshik Kim; Yun-Ui Bae; Haekyung Lee; Hyoungnae Kim; Jin Seok Jeon; Hyunjin Noh; Dong Cheol Han; Dong Won Byun; Sang Hyun Kim; Hyeong Kyu Park; Seongho Ryu; Soon Hyo Kwon
Journal:  BMJ Open Diabetes Res Care       Date:  2020-09

Review 2.  Mitochondrial Dysfunction and Diabetic Nephropathy: Nontraditional Therapeutic Opportunities.

Authors:  Ping Na Zhang; Meng Qi Zhou; Jing Guo; Hui Juan Zheng; Jingyi Tang; Chao Zhang; Yu Ning Liu; Wei Jing Liu; Yao Xian Wang
Journal:  J Diabetes Res       Date:  2021-12-09       Impact factor: 4.011

3.  Effect of bariatric surgery on circulating and urinary mitochondrial DNA copy numbers in obesity with or without diabetes.

Authors:  Mihae Seo; Hyoungnae Kim; Hyunjin Noh; Jin Seok Jeon; Dong Won Byun; Sang Hyun Kim; Hye Jeong Kim; Kyoil Suh; Hyeong Kyu Park; Soon Hyo Kwon
Journal:  BMJ Open Diabetes Res Care       Date:  2020-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.